Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.

Collins LM, Gavin AM, Walsh S, Sullivan AM, Wyatt SL, O'Keeffe GW, Nolan YM, Toulouse A.

Springerplus. 2014 Apr 28;3:205. doi: 10.1186/2193-1801-3-205. eCollection 2014.

3.
4.

A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

Boix J, Padel T, Paul G.

Behav Brain Res. 2015 May 1;284:196-206. doi: 10.1016/j.bbr.2015.01.053. Epub 2015 Feb 16.

5.
6.

Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.

Lee EY, Lee JE, Park JH, Shin IC, Koh HC.

Toxicol Lett. 2012 Sep 18;213(3):332-44. doi: 10.1016/j.toxlet.2012.07.016. Epub 2012 Jul 27.

PMID:
22842585
7.

Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.

Jin F, Wu Q, Lu YF, Gong QH, Shi JS.

Eur J Pharmacol. 2008 Dec 14;600(1-3):78-82. doi: 10.1016/j.ejphar.2008.10.005. Epub 2008 Oct 10.

PMID:
18940189
8.

N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.

Guan J, Krishnamurthi R, Waldvogel HJ, Faull RL, Clark R, Gluckman P.

Brain Res. 2000 Mar 24;859(2):286-92.

PMID:
10719076
9.

Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.

Neurobiol Dis. 2006 May;22(2):421-34. Epub 2006 Feb 9.

PMID:
16480889
10.

Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.

Stott SR, Barker RA.

Eur J Neurosci. 2014 Mar;39(6):1042-56. doi: 10.1111/ejn.12459. Epub 2013 Dec 26.

PMID:
24372914
12.

Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.

Yuan H, Sarre S, Ebinger G, Michotte Y.

J Neurosci Methods. 2005 May 15;144(1):35-45. Epub 2004 Dec 8.

PMID:
15848237
13.

Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Shin KS, Choi HS, Zhao TT, Suh KH, Kwon IH, Choi SO, Lee MK.

Arch Pharm Res. 2013 Jun;36(6):759-67. doi: 10.1007/s12272-013-0051-4. Epub 2013 Mar 29.

PMID:
23539311
14.

Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

Walsh S, Mnich K, Mackie K, Gorman AM, Finn DP, Dowd E.

Brain Res Bull. 2010 Apr 5;81(6):543-8. doi: 10.1016/j.brainresbull.2010.01.009. Epub 2010 Jan 25.

15.

Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Barnum CJ, Chen X, Chung J, Chang J, Williams M, Grigoryan N, Tesi RJ, Tansey MG.

J Parkinsons Dis. 2014;4(3):349-60. doi: 10.3233/JPD-140410.

16.

Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.

Crotty S, Fitzgerald P, Tuohy E, Harris DM, Fisher A, Mandel A, Bolton AE, Sullivan AM, Nolan Y.

Eur J Neurosci. 2008 Jan;27(2):294-300. doi: 10.1111/j.1460-9568.2007.06018.x. Epub 2008 Jan 11.

PMID:
18190522
17.

Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Sleeman IJ, Boshoff EL, Duty S.

Neuropharmacology. 2012 Dec;63(7):1268-77. doi: 10.1016/j.neuropharm.2012.07.029. Epub 2012 Aug 10.

PMID:
22971544
18.

Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease.

Rizelio V, Szawka RE, Xavier LL, Achaval M, Rigon P, Saur L, Matheussi F, Delattre AM, Anselmo-Franci JA, Meneses M, Ferraz AC.

Braz J Med Biol Res. 2010 Jan;43(1):85-95. Epub 2009 Dec 4.

19.

Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.

Park HJ, Zhao TT, Lee KS, Lee SH, Shin KS, Park KH, Choi HS, Lee MK.

Neurochem Int. 2015 Apr-May;83-84:19-27. doi: 10.1016/j.neuint.2015.01.003. Epub 2015 Mar 3.

PMID:
25747493
20.

Supplemental Content

Support Center